EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Silico Characterization of Pathogenic ESR2 Coding and UTR Variants as Oncogenic Potential Biomarkers in Hormone-Dependent Cancers

Hakeemah Al-Nakhle iD, Zainab Almoerifi, Layan Alharbi, Mashael Alayoubi, Rawan Alharbi

Genes · 2025

DOI: 10.3390/genes16101144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Hakeemah Al-Nakhle und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taibah University, Madinah 42353, Saudi Arabia. Hauptthemen laut MEDLINE: Estrogen Receptor beta, Biomarkers, Tumor, Breast Neoplasms, Neoplasms. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The ESR2 gene encodes Estrogen Receptor-β1 (ERβ1), a putative tumor suppressor in hormone-dependent malignancies. Although ERβ biology has been studied extensively at the expression level, the functional impact of nonsynonymous SNPs (nsSNPs) and untranslated-region (UTR) variants in ESR2 remains underexplored.

Methods

We retrieved variants from Ensembl and performed an integrative in silico assessment using PredictSNP, I-Mutant, MUpro, HOPE, MutPred2, and CScape for pathogenicity, oncogenicity and structural stability; STRING/KEGG/GO for pathway context; RegulomeDB and polymiRTS for regulatory effects; and cBioPortal for pan-cancer clinical outcomes (breast (BRCA), endometrial (UCEC), and ovarian (OV)). We evaluated effects of nsSNPs on ERβ1 stability, ligand-binding/DNA-binding domains, co-factor recruitment, and post-transcriptional regulation.

Results

Across tools, 93 missense nsSNPs were consistently predicted to be deleterious. Notably, several variants were found to destabilize ERβ1, particularly within the ligand-binding domains (LBD) and DNA-binding domains (DBD). Putative oncogenic drivers R198P and D154N showed high CScape scores and very low population frequencies, consistent with pathogenicity. Several substitutions were predicted to impair coactivator binding and disrupt interactions with key transcriptional partners, including JUN, NCOA1, and SP1. At the post-transcriptional level, rs139004885 was predicted to disrupt miRNA binding, while 3′UTR rs4986938 showed strong regulatory potential and comparatively high population frequency; by contrast, most other identified SNPs were rare. Clinically, pan-cancer survival analyses indicated worse overall survival (OS) in BRCA for ESR2-Altered cases (HR ≈ 2.25; q < 0.001), but better OS in UCEC (HR ≈ 0.24; q ≈ 0.014) and OV (HR ≈ 0.29; q < 0.001), highlighting a tumor-type-specific association.

Conclusions

This integrative analysis prioritizes high-impact ESR2 variants that likely impair ERβ1 structure and shows context-dependent clinical effects. Despite their generally low frequency (except for rs4986938), prospective validation linking variant class to ERβ expression and survival outcomes is needed to support biomarker development and therapeutic applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Estrogen Receptor betaBiomarkers, TumorBreast NeoplasmsNeoplasmsOvarian NeoplasmsEndometrial NeoplasmsHumansPolymorphism, Single NucleotideFemaleComputer SimulationGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

ESR2UTR variantsestrogen receptor beta (ERβ1)in silico analysisnsSNPsprotein stability

Substanzen

Estrogen Receptor betaESR2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taibah University, Madinah 42353, Saudi Arabia.
  • Health and Life Research Center, Taibah University, Madinah 42353, Saudi Arabia.

ORCID-Profile: Hakeemah Al-Nakhle

Zitieren

APA

Al-Nakhle, H., Almoerifi, Z., Alharbi, L., Alayoubi, M., & Alharbi, R. (2025). In Silico Characterization of Pathogenic ESR2 Coding and UTR Variants as Oncogenic Potential Biomarkers in Hormone-Dependent Cancers. Genes. https://doi.org/10.3390/genes16101144

Vancouver

Al-Nakhle H, Almoerifi Z, Alharbi L, Alayoubi M, Alharbi R. In Silico Characterization of Pathogenic ESR2 Coding and UTR Variants as Oncogenic Potential Biomarkers in Hormone-Dependent Cancers. Genes. 2025. doi:10.3390/genes16101144

BibTeX
@article{AlNakhle2025,
  author = {Al-Nakhle, Hakeemah and Almoerifi, Zainab and Alharbi, Layan and Alayoubi, Mashael and Alharbi, Rawan},
  title = {In Silico Characterization of Pathogenic ESR2 Coding and UTR Variants as Oncogenic Potential Biomarkers in Hormone-Dependent Cancers},
  journal = {Genes},
  year = {2025},
  doi = {10.3390/genes16101144}
}
Kostenlos starten →